Differential and kinetic effects of cell cycle inhibitors on neoplastic and primary astrocytes

References

• Langan TJ, Slater MC. Cell cycling of astrocytes and their precursors in primary cultures: a mevalonate requirement identified in late G1, but before the G1/S transition, involves polypeptides. J Neurochem 1991; 56:1058-68; PMID:1993888; http://dx.doi.org/10.1111/j.1471-4159.1991.tb02029.x
   PubMed Web of Science ®Google Scholar
• Langan TJ. Deterministic role of the cell cycle in newborn brain development and in brain injury. Semin Neurol 1993; 13:92-9; PMID:8511424; http://dx.doi.org/10.1055/s-2008-1041112
   PubMed Web of Science ®Google Scholar
• Langan TJ, Slater MC. Astrocytes derived from long-term primary cultures recapitulate features of astrogliosis as they re-enter the cell division cycle. Brain Res 1992; 577:200-9; PMID:1606495; http://dx.doi.org/10.1016/0006-8993(92)90275-E
   PubMed Web of Science ®Google Scholar
• Amat JA, Ishiguro H, Nakamura K, Norton WT. Phenotypic diversity and kinetics of proliferating microglia and astrocytes following cortical stab wounds. Glia 1996; 16:368-82; PMID:8721677; http://dx.doi.org/10.1002/(SICI)1098-1136(199604)16:4%3c368::AID-GLIA9%3e3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Di Giovanni S, Movsesyan V, Ahmed F, Cernak I, Schinelli S, Stoica B, Faden AI. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci USA 2005; 102:8333-8; PMID:15923260; http://dx.doi.org/10.1073/pnas.0500989102
   PubMed Web of Science ®Google Scholar
• Hulleman E, Helin K. Molecular mechanisms in gliomagenesis. Adv Cancer Res 2005; 94:1-27; PMID:16095998; http://dx.doi.org/10.1016/S0065-230X(05)94001-3
   PubMed Web of Science ®Google Scholar
• Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treat Res 2015; 163:15-30; PMID:25468223; http://dx.doi.org/10.1007/978-3-319-12048-5_2
   PubMedGoogle Scholar
• Li W, Li K, Zhao L, Zou H. Bioinformatics analysis reveals disturbance mechanism of MAPK signaling pathway and cell cycle in Glioblastoma multiforme. Gene 2014; 547:346-50; PMID:24967941; http://dx.doi.org/10.1016/j.gene.2014.06.042
   PubMed Web of Science ®Google Scholar
• Koyama-Nasu R, Nasu-Nishimura Y, Todo T, Ino Y, Saito N, Aburatani H, Funato K, Echizen K, Sugano H, Haruta R, et al. The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. Oncogene 2013; 32:3840-5; PMID:22964630; http://dx.doi.org/10.1038/onc.2012.399
   PubMed Web of Science ®Google Scholar
• Saggioro FP, Neder L, Stávale JN, Paixão-Becker AN, Malheiros SM, Soares FA, Pittella JE, Matias CC, Colli BO, Carlotti CG Jr, et al. Fas, FasL, and cleaved caspases 8 and 3 in glioblastomas: a tissue microarray-based study. Pathol Res Pract 2014; 210:267-73; PMID:24561085; http://dx.doi.org/10.1016/j.prp.2013.12.012
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res 2015; 163:1-14; PMID:25468222; http://dx.doi.org/10.1007/978-3-319-12048-5_1
   PubMedGoogle Scholar
• Dey M, Lin Y, Melkonian S, Lam S. Prognostic factors and survival in primary adult high grade brainstem astrocytoma: a population based study from 1973-2008. J Clin Neurosci 2014; 21:1298-303; PMID:24674698; http://dx.doi.org/10.1016/j.jocn.2013.12.011
   PubMed Web of Science ®Google Scholar
• Bambury RM, Morris PG. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. Expert Rev Anticancer Ther 2014; 14:955-64; PMID:24814143; http://dx.doi.org/10.1586/14737140.2014.916214
   PubMed Web of Science ®Google Scholar
• Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220-7; PMID:16936740; http://dx.doi.org/10.1038/sj.onc.1209615
   PubMed Web of Science ®Google Scholar
• Karlsson-Rosenthal C, Millar JB. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006; 16:285-92; PMID:16682204; http://dx.doi.org/10.1016/j.tcb.2006.04.002
   PubMed Web of Science ®Google Scholar
• Langan TJ, Iimori Y, White G, Volpe JJ. Regulation of sterol synthesis and of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lipoproteins in glial cells in primary culture. J Neurosci Res 1987; 17:361-6; PMID:2887663; http://dx.doi.org/10.1002/jnr.490170406
   PubMed Web of Science ®Google Scholar
• Langan TJ, Volpe JJ. Cell cycle-specific requirement for mevalonate, but not for cholesterol, for DNA synthesis in glial primary cultures. J Neurochem 1987; 49:513-21; PMID:3648095; http://dx.doi.org/10.1111/j.1471-4159.1987.tb02894.x
   PubMed Web of Science ®Google Scholar
• Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J Neurochem 1998; 70:2397-405; PMID:9603204; http://dx.doi.org/10.1046/j.1471-4159.1998.70062397.x
   PubMed Web of Science ®Google Scholar
• Quesney-Huneeus V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979; 76:5056-60; PMID:291922; http://dx.doi.org/10.1073/pnas.76.10.5056
   PubMed Web of Science ®Google Scholar
• Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004; 229:567-85; PMID:15229351
   PubMed Web of Science ®Google Scholar
• Volpe JJ, Obert KA. Coordinate regulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A synthase but not 3-hydroxy-3-methylglutaryl coenzyme A reductase in C-6 glia. Arch Biochem Biophys 1981; 212:88-97; PMID:6118099; http://dx.doi.org/10.1016/0003-9861(81)90346-5
   PubMed Web of Science ®Google Scholar
• Maltese WA. Three-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 1983; 33:1294-9; PMID:6684224; http://dx.doi.org/10.1212/WNL.33.10.1294
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Nagata Y, Abe T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol 1997; 34:233-9; PMID:9258815; http://dx.doi.org/10.1023/A:1005753523949
   PubMed Web of Science ®Google Scholar
• Murakami M, Goto T, Saito Y, Goto S, Kochi M, Ushio Y. The inhibitory effect of simvastatin on growth in malignant gliomas–with special reference to its local application with fibrin glue spray in vivo. Int J Oncol 2001; 19:525-31; PMID:11494031
   PubMed Web of Science ®Google Scholar
• Li V, Kelly K, Schrot R, Langan TJ. Cell cycle kinetics and commitment in newborn, adult, and tumoral astrocytes. Brain Res Dev Brain Res 1996; 96:138-47; PMID:8922676; http://dx.doi.org/10.1016/0165-3806(96)00109-5
   PubMedGoogle Scholar
• Langan TJ, Chou RC. Synchronization of mammalian cell cultures by serum deprivation. Methods Mol Biol 2011; 761:75-83; PMID:21755442; http://dx.doi.org/10.1007/978-1-61779-182-6_5
   PubMedGoogle Scholar
• Larsson O, Zetterberg A. Effects of 25-hydroxycholesterol, cholesterol, and isoprenoid derivatives on the G1 progression in Swiss 3T3 cells. J Cell Physiol 1986; 129:94-102; PMID:3760035; http://dx.doi.org/10.1002/jcp.1041290114
   PubMed Web of Science ®Google Scholar
• Larsson O. Role of biosynthesis of cholesterol and isoprenoid derivatives in regulation of G1 progression and cell proliferation of 3T6 cells. J Cell Physiol 1987; 133:163-8; PMID:3667703; http://dx.doi.org/10.1002/jcp.1041330121
   PubMed Web of Science ®Google Scholar
• Larsson O, Wejde J. Dolichol delays G1-arrest for one cell cycle in human fibroblasts subjected to depletion of serum or mevalonate. J Cell Sci 1992; 103:1065-72; PMID:1487489
   PubMed Web of Science ®Google Scholar
• Choi JW, Jung SE. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J Pharmacol Exp Ther 1999; 289:572-9; PMID:10087052
   PubMed Web of Science ®Google Scholar
• Gonzalez J, Gilbert MR. Treatment of astrocytomas. Curr Opin Neurol 2005; 18:632-8; PMID:16280673; http://dx.doi.org/10.1097/01.wco.0000191510.14627.d2
   PubMed Web of Science ®Google Scholar
• Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24:1253-65; PMID:16525180; http://dx.doi.org/10.1200/JCO.2005.04.5302
   PubMed Web of Science ®Google Scholar
• Mathieu D, Fortin D. The role of chemotherapy in the treatment of malignant astrocytomas. Can J Neurol Sci 2006; 33:127-40; PMID:16736721; http://dx.doi.org/10.1017/S0317167100004881
   PubMed Web of Science ®Google Scholar
• Cory AH, He AW, Cory JG. Multifactorial mechanisms of drug resistance in tumor cell populations selected for resistance to specific chemotherapeutic agents. Adv Enzyme Regul 1998; 38:3-18; PMID:9762343; http://dx.doi.org/10.1016/S0065-2571(97)00003-4
   PubMedGoogle Scholar
• Wettergren Y, Kullberg A, Levan G. Drug-specific rearrangements of chromosome 12 in hydroxyurea-resistant mouse SEWA cells: support for chromosomal breakage model of gene amplification. Somat Cell Mol Genet 1994; 20:267-85; PMID:7974003; http://dx.doi.org/10.1007/BF02254717
   PubMedGoogle Scholar
• Zhou BS, Hsu NY, Pan BC, Doroshow JH, Yen Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 1995; 55:1328-33; PMID:7882331
   PubMed Web of Science ®Google Scholar
• Levenson VV, Davidovich IA, Roninson IB. Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 2000; 60:5027-30; PMID:11016623
   PubMed Web of Science ®Google Scholar
• Kinsella AR, Smith D, Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 1997; 75:935-45; PMID:9083327; http://dx.doi.org/10.1038/bjc.1997.164
   PubMed Web of Science ®Google Scholar
• Carter GL, Thompson DP, Cory JG. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase. Cancer Commun 1989; 1:13-20; PMID:2701080
   PubMedGoogle Scholar
• Johnson CE, Hughes K, Cory JG. Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants. Cancer Commun 1991; 3:341-9; PMID:1760249
   PubMedGoogle Scholar
• Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999; 96:7797-7802; PMID:10393901; http://dx.doi.org/10.1073/pnas.96.14.7797
   PubMed Web of Science ®Google Scholar
• Petras SF, Lindsey S, Harwood HJ Jr. HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells. J Lipid Res 1999; 40:24-38; PMID:9869647
   PubMed Web of Science ®Google Scholar
• Bergstrom JD, Bostedor RG, Rew DJ, Geissler WM, Wright SD, Chao YS. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim Biophys Acta 1998; 1389:213-21; PMID:9512650; http://dx.doi.org/10.1016/S0005-2760(97)00182-3
   PubMed Web of Science ®Google Scholar
• Li AC, Tanaka RD, Callaway K, Fogelman AM, Edwards PA. Localization of 3-hydroxy-3-methylglutaryl CoA reductase and 3-hydroxy-3-methylglutaryl CoA synthase in the rat liver and intestine is affected by cholestyramine and mevinolin. J Lipid Res 1988; 29:781-96; PMID:2902179
   PubMed Web of Science ®Google Scholar
• Singer II, Scott S, Kazazis DM, Huff JW. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc Natl Acad Sci USA 1988; 85:5264-8; PMID:3293052 http://dx.doi.org/10.1073/pnas.85.14.5264
   PubMed Web of Science ®Google Scholar
• Stone BG, Evans CD, Prigge WF, Duane WC, Gebhard RL. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects. J Lipid Res 1989; 30:1943-52; PMID:2621421
   PubMed Web of Science ®Google Scholar
• Dawson PA, Metherall JE, Ridgway ND, Brown MS, Goldstein JL. Genetic distinction between sterol-mediated transcriptional and posttranscriptional control of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 1991; 266:9128-34; PMID:1673968
   PubMed Web of Science ®Google Scholar
• Rao KN. The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis (review). Anticancer Res 1995; 15:309-14; PMID:7762999
   PubMed Web of Science ®Google Scholar
• Morgan JS, Creasey DC, Wright JA. Evidence that the antitumor agent hydroxyurea enters mammalian cells by a diffusion mechanism. Biochem Biophys Res Commun 1986; 134:1254-9; PMID:3753869 http://dx.doi.org/10.1016/0006-291X(86)90385-2
   PubMed Web of Science ®Google Scholar